

Substantive Exam 1449/PTO

PTO/SB/08A (05-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1

1

C

2

Attorney Docket Number

49321-103

Complete if Known

Application Number	10/698.963
--------------------	------------

10/698.963

Filing Date	October 31, 2003
-------------	------------------

October 31, 2003

First Named Inventor	Kathryn Chung
----------------------	---------------

Kathryn Chung

Art Unit	1614
----------	------

1614

Examiner Name

Attorney Docket Number	49321-103
------------------------	-----------

U.S. PATENT DOCUMENTS

[illegible]


FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	† ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
/LW/		WO-01/68114 A1	09-13-2001			
/LW/		EP-1020469 A2	07-19-2000			
/LW/		WO-97/46527	12-11-1997			
/LW/		EP-0698390 A1	02-28-1996			

Examiner Signature	/Leonard Williams/ (06/22/2007)	Date Considered	
-----------------------	---------------------------------	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 04/30/2003. OMB 0551-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/698,963		
		Filing Date	October 31, 2003		
		First Named Inventor	Kathryn Chung		
		Art Unit	1614		
		Examiner Name			
Sheet	2	of	2	Attorney Docket Number	49321-103

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/LW/		AARSLAND ET AL., <i>Donepezil for Cognitive Impairment in Parkinson's Disease: a Randomised Controlled Study</i> , J NEUROL NEUROSURG PSYCHIATRY, 72:708-712, 2002.	
/LW/		HARDAN ET AL., <i>A Retrospective Open Trial of Adjunctive Donepezil in Children and Adolescents with Autistic Disorder</i> , JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 12(3):237-241, 2002.	
/LW/		TAMMENMAA ET AL., <i>Cholinergic Medication for Neuroleptic-Induced Tardive Dyskinesia</i> , COCHRANE DATABASE SYST. REV., CD000207, 2002.	
/LW/		CAROFF ET AL., <i>Treatment of Tardive Dyskinesia with Donepezil: A Pilot Study</i> , J CLIN PSYCHIATRY, 62(10):772-775, 2001.	
/LW/		CAROFF ET AL., <i>Treatment of Tardive Dyskinesia with Donepezil</i> , J CLIN PSYCHIATRY, 62(2):128-129, 2001.	
/LW/		LITVAN ET AL., <i>Randomized Placebo-Controlled Trial of Donepezil in Patients with Progressive Supranuclear Palsy</i> , NEUROLOGY, 57:467-473, 2001.	
/LW/		WILENS ET AL., <i>Adjunctive Donepezil in Attention Deficit Hyperactivity Disorder Youth: Case Series</i> , JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 10(3):217-222, 2000.	
/LW/		MENDEZ ET AL., <i>Use of Donepezil for Vascular Dementia: Preliminary Clinical Experience</i> , J NEUROPSYCHIATRY CLIN NEUROSCI, 11(2):268-270, 1999.	

Examiner Signature	/Leonard Williams/ (06/22/2007)	Date Considered	
--------------------	---------------------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.